SNORD114-5: A Potential Drug Target and Biomarker (G767581)

Target Name: SNORD114-5

NCBI ID: G767581

SNORD114-5

Other Name(s): small nucleolar RNA, C/D box 114-5 | Small nucleolar RNA, C/D box 114-5 | 14q(II-5)

SNORD114-5: A Potential Drug Target and Biomarker

Small nucleolar RNA (snRNA) is a class of non-coding RNAs that play a critical role in various cellular processes, including DNA replication, gene expression, and chromatin regulation. One of the well-known snRNAs is SNORD114-5, which is located within the C/D box region on chromosome 17. In this article, we will discuss the potential implications of SNORD114-5 as a drug target and biomarker.

SNORD114-5 Structure and Function

SNORD114-5 is a 22.9-kb long RNA molecule, composed of 10 exons (1-10) and a poly(A) tail length of 184nt. SNORD114-5 is predominantly expressed in the brain, with a relatively low expression in other tissues and cells. It is localized to the cytoplasm and is associated with the nuclear envelope.

SNORD114-5 has been shown to play a role in various cellular processes, including the regulation of gene expression, DNA replication, and chromatin structure. One of the most significant functions of SNORD114-5 is its role in the regulation of microRNA (miRNA) expression. miRNA is a small non-coding RNA molecule that plays a critical role in post-transcriptional gene regulation by binding to specific mRNAs to facilitate their degradation.

Studies have shown that SNORD114-5 can interact with several miRNAs, including Let-7, which is a well-known miRNA that plays a role in the regulation of cellular processes such as cell growth, differentiation, and apoptosis. Additionally, SNORD114-5 has been shown to interact with miRNA-621, a microRNA that is involved in the regulation of cell cycle progression and apoptosis.

SNORD114-5 as a Drug Target

The potential drug target for SNORD114-5 is based on its role in the regulation of miRNA expression. miRNA molecules have been shown to play a critical role in the regulation of cellular processes, including cancer progression, and SNORD114-5 may be a useful target for the development of therapeutic agents that target miRNA regulation.

One of the main advantages of targeting SNORD114-5 is its specificity for miRNA regulation. The C/D box region of SNORD114-5 is known for its ability to interact with certain miRNAs, making it a potential target for small molecule inhibitors. Additionally, the well-known effects of let-7 and miRNA-621 on cellular processes such as cell growth, apoptosis, and cell cycle progression suggest that targeting SNORD114-5 may have a beneficial effect on cellular processes that are affected by these miRNAs.

SNORD114-5 as a Biomarker

SNORD114-5 may also be used as a biomarker for various diseases, including cancer. The regulation of miRNA expression is a well-established mechanism for cancer development, and targeting SNORD114-5 with small molecule inhibitors may be a potential approach for the development of therapeutic agents for cancer.

Studies have shown that SNORD114-5 is highly expressed in various types of cancer, including breast, lung, and ovarian cancer. Additionally, studies have shown that targeting SNORD114-5 with small molecule inhibitors has the potential to inhibit the growth and metastasis of cancer. cells. This suggests that SNORD114-5 may be an attractive biomarker for the development of therapeutic agents for cancer.

Conclusion

In conclusion, SNORD114-5 is a potential drug target and biomarker that has been shown to play a role in various cellular processes, including the regulation of miRNA expression and the regulation of cellular

Protein Name: Small Nucleolar RNA, C/D Box 114-5

The "SNORD114-5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD114-5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets